Company profile: Circassia
1.1 - Company Overview
Company description
- Provider of point-of-care asthma diagnostics and management solutions, including NIOX VERO and FeNO by NIOX for measuring fractional exhaled nitric oxide to assess airway inflammation, used by physicians worldwide to aid diagnosis and management, with dedicated customer service and after-sales support.
Products and services
- FeNO by NIOX: FeNO-based products that deliver clear airway inflammation measurements to assist physicians worldwide in diagnosing and managing asthma using market-leading NIOX components
- NIOX VERO: Point-of-care device measuring fractional exhaled nitric oxide (FeNO) to help healthcare professionals assess airway inflammation in asthma patients and support diagnosis and management
- Customer Service and After Sales Support: Global-scale assistance that supplies outstanding customer service and after sales support to physicians using NIOX products, supporting ongoing asthma diagnosis and management
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Circassia
CellPoint
HQ: The Netherlands
Website
- Description: Provider of point-of-care CAR-T therapy solutions enabling clinicians to retarget patient immune cells to treat hematological malignancies, with a 6-day manufacturing process powered by the proprietary xCellit real-time monitoring software system that allows for 1 week vein-to-vein time, making therapies more affordable and accessible.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CellPoint company profile →
Telesta Therapeutics
HQ: Canada
Website
- Description: Provider of transformative human therapeutics, focused on licensing, acquisition, development, manufacturing and commercialization of novel medicines addressing major unmet medical needs, particularly in oncology; anchor product MCNA has completed a Phase III pivotal study.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Telesta Therapeutics company profile →
Arch Oncology
HQ: United States
Website
- Description: Provider of venture-stage biopharmaceutical solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arch Oncology company profile →
Aridis Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel, differentiated biopharmaceutical therapies for infectious diseases, including AR-301, a fully human monoclonal antibody targeting S. aureus alpha-toxin to treat ventilator-associated pneumonia; AR-320, a long-acting antibody to prevent ventilator-associated pneumonia; AR-501, inhaled gallium citrate for bacterial lung infections in cystic fibrosis patients; and the MabIgX platform to discover rare, potent human monoclonal antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aridis Pharmaceuticals company profile →
Tizona Therapeutics
HQ: United States
Website
- Description: Provider of next-generation immunotherapies, including TTX-080, an investigational antibody targeting HLA-G evaluated as monotherapy and in combination in patients with advanced cancers; TTX-030, a monoclonal antibody inhibiting CD39 studied with an approved anti-PD-1 agent and standard chemotherapy in adults with advanced cancer; and TZ-040, a pre-clinical program anticipated to enter IND-enabling studies targeting novel immuno-modulatory molecules.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tizona Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Circassia
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Circassia
2.2 - Growth funds investing in similar companies to Circassia
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Circassia
4.2 - Public trading comparable groups for Circassia
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →